about
Transarterial chemoembolization using drug eluting beads for the treatment of hepatocellular carcinoma: Now and futureTransarterial therapy: an evolving treatment modality of hepatocellular carcinomaPrognostication and response assessment in liver and pancreatic tumors: The new imagingAsian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma.Lipiodol transarterial chemoembolization for hepatocellular carcinoma: A systematic review of efficacy and safety data.Review of asian experience of thermal ablation techniques and clinical practice.Image-guided tumor ablation: standardization of terminology and reporting criteriaInhibitory effect of antisense vascular endothelial growth factor RNA on the profile of hepatocellular carcinoma cell line in vitro and in vivo.Symptom management in hepatocellular carcinomaUse of yttrium-90 microspheres in patients with advanced hepatocellular carcinoma and portal vein thrombosis.Chemoembolization for hepatocellular carcinoma: comprehensive imaging and survival analysis in a 172-patient cohort.Confirmation of drug delivery after liver chemoembolization: direct tissue doxorubicin measurement by UHPLC-MS-MS.Hepatocellular carcinoma treated with transarterial chemoembolization: dynamic perfusion-CT in the assessment of residual tumor.Prognostic value of α-fetoprotein and des-γ-carboxy prothrombin responses in patients with hepatocellular carcinoma treated with transarterial chemoembolization.Embolisation of cancer: what is the evidence?Laparoscopic ablation of hepatocellular carcinoma in cirrhotic patients unsuitable for liver resection or percutaneous treatment: a cohort studyTransarterial chemoembolization using gelatin sponges or microspheres plus lipiodol-doxorubicin versus doxorubicin-loaded beads for the treatment of hepatocellular carcinomaIntraprocedural transcatheter intra-arterial perfusion MRI as a predictor of tumor response to chemoembolization for hepatocellular carcinomaPharmacotherapy of hepatocellular carcinoma.Institutional guidelines and ongoing studies in management of liver tumours: the experience of the European Institute of Oncology.The role of (18)F-FDG positron emission tomography in the follow-up of liver tumors treated with (90)Yttrium radioembolization.Interventional radiological treatment of hepatocellular carcinoma: an update.NCCN clinical practice guidelines in oncology: hepatobiliary cancersPharmacokinetic study of conventional sorafenib chemoembolization in a rabbit VX2 liver tumor model.Transarterial injection of recombinant human type-5 adenovirus H101 in combination with transarterial chemoembolization (TACE) improves overall and progressive-free survival in unresectable hepatocellular carcinoma (HCC)Transcatheter intraarterial therapies: rationale and overviewHepatic resection provided long-term survival for patients with intermediate and advanced-stage resectable hepatocellular carcinoma.Implications of discordant findings between hepatic angiography and cross-sectional imaging in transplant candidates with hepatocellular carcinoma.Clinical effects of transcatheter hepatic arterial embolization with holmium-166 poly(L-lactic acid) microspheres in healthy pigs.Chloroquine promotes the anticancer effect of TACE in a rabbit VX2 liver tumor model.FDG-PET for evaluating the antitumor effect of intraarterial 3-bromopyruvate administration in a rabbit VX2 liver tumor modelGelatin sponge microparticles for the treatment of the spontaneous rupture of hepatocellular carcinoma hemorrhage.TACE versus TAE as therapy for hepatocellular carcinoma.Drug-eluting particles in the treatment of HCC: chemoembolization with doxorubicin-loaded DC Bead.Effect of b value on monitoring therapeutic response by diffusion-weighted imaging.Transarterial sorafenib chemoembolization: preliminary study of technical feasibility in a rabbit model.Intra-arterial therapies for hepatocellular carcinoma: where do we stand?Transarterial chemoembolization of hepatocellular carcinoma. Agents and drugs: an overview. Part 1.NCCN Guidelines Insights: Hepatobiliary Cancers, Version 1.2017Arsenic trioxide: marked suppression of tumor metastasis potential by inhibiting the transcription factor Twist in vivo and in vitro.
P2860
Q26771776-94A415E0-F068-44E8-BEB7-9F1B20613221Q26866514-854D1093-3FBC-4926-AADA-42BA958D171DQ27021568-8B6B0E30-EE9C-4A3B-80A5-6F5FEF09D303Q30479629-016AD513-0E99-4C9B-BE13-710E1045E2EEQ31036824-85C41466-0D40-4B10-AEA4-ABFEE8327A3CQ31144294-F71669EB-CBC5-460D-9F39-D2905E6ABE19Q31161842-C96C05C2-3536-4F35-9F8B-A186574A325FQ33868191-78F752A0-C45F-4582-ACFF-6F38304471F5Q33897458-4F8B1302-9FD3-422C-AD29-8EABE1A0FD35Q34155198-732D64C1-4583-4DCD-9A19-7045C23DDB57Q34168811-EE1C3DA0-12B6-4B58-8DE0-6CF89A4C47FEQ34210319-7D9EFC39-FE74-449E-85EF-95BF0F7A02F3Q34428795-A9195153-01A4-49F7-8622-3598A89A06FDQ34530671-A70E0B04-16E9-466E-8407-123919A77A47Q34533357-99A15404-EB64-4B8A-835C-DE09885178C0Q34600274-603D1C82-D0F0-4284-A0D0-234D019E056DQ34975108-69D43775-DFF5-499E-BCC1-73E634E64A43Q35203257-E7341FF8-486D-4AC4-B699-4C32C0A50885Q35593957-B2D045CD-A3E9-4BAC-8AFF-29FD65B12D29Q35602256-5A11AEF5-C8A1-4F26-843B-2BC338C746DCQ35656582-DCC2C5F4-7B3A-4456-BA4A-532B15F4C514Q35675131-AE08E292-12BD-440B-94AA-E5022EFAE78BQ35703937-EAC63E45-BEF3-464F-AB21-07A266455EDCQ35720473-1A44CEF2-F010-4660-AB60-3CADB49DE485Q35809215-907063BA-102A-4781-A639-44CCDEA55CE3Q36104314-67C3F7BC-3066-4B06-B704-81A2437AA6E7Q36646019-789DBDE2-6519-4722-9574-15CC24F36041Q36728700-362AE9D3-D4C9-4FA0-B9D2-874C0EE9DB70Q36738344-CAD3377A-6A24-4E2D-92E2-71C8AB44A1FAQ36746840-A85A7355-27C2-433E-BFBE-A43016FA79F1Q37063643-B1E3864C-704E-430D-BE1C-28058B34A276Q37288268-1E3B962B-F2D3-4309-9093-C4A40C710FACQ37300023-54305655-05E2-44F7-B938-96422C388B79Q37300028-40978CD6-FFC5-437A-AE78-A4D7508ACC4DQ37362711-970B9239-22EA-4DD2-AD11-1FC1D7A25CFDQ37704703-49E38141-04BE-4C1A-B698-9F2538E18C0DQ37734300-DF0234F9-8A1A-46A9-A06C-62A6639B73D9Q38081222-7209371B-E17F-433C-B3C3-6CF6C49147CAQ38801422-C972E3A9-BE02-4AF9-9C6A-554107ECD49AQ39001861-1A11C121-3283-4F16-AC95-81BBD8035998
P2860
description
2002 nî lūn-bûn
@nan
2002 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Chemoembolization of hepatocellular carcinoma.
@ast
Chemoembolization of hepatocellular carcinoma.
@en
Chemoembolization of hepatocellular carcinoma.
@nl
type
label
Chemoembolization of hepatocellular carcinoma.
@ast
Chemoembolization of hepatocellular carcinoma.
@en
Chemoembolization of hepatocellular carcinoma.
@nl
prefLabel
Chemoembolization of hepatocellular carcinoma.
@ast
Chemoembolization of hepatocellular carcinoma.
@en
Chemoembolization of hepatocellular carcinoma.
@nl
P2093
P1476
Chemoembolization of hepatocellular carcinoma.
@en
P2093
Douglas E Ramsey
Jean-Francois H Geschwind
Lily Y Kernagis
Michael C Soulen
P304
P356
10.1016/S1051-0443(07)61789-8
P433
P577
2002-09-01T00:00:00Z